New Method for Testing Induced Pluripotent Stem Cells Differentiation Potential Could Lead to Safer and More Potent Treatments

Share Article

Though the discovery of Induced Pluripotent Stem Cells (iPSCs) has great potential to help in the development of regenerative medicine therapies, the attempts to discover how safe and potent the use of iPSCs are in treatment of diseases has been inconclusive or contradictory. Atlas Regeneration Inc., working together with Insilico Medicine, has developed a method for using pathway activity analysis to test for differentiation potential that makes iPSCs effective much more quickly than was previously possible.

People Behind Regeneration

Regeneration Intelligence is unique among pathway analysis platforms. Using our algorithm along with a proprietary pathway database, we established for the first time pathway activation profiles of iPS.

The discovery of human induced pluripotent stem cells (iPSCs) in 2006 completely revolutionized the field of stem cell biology. iPSC lines have become powerful tools that can be used to study human embryonic development, as model systems for human diseases. They are also helpful as a renewable source for regenerative medicine, where these cells are expected to play a key role in the development of many regenerative medicine therapies.

During recent collaboration, two companies, Atlas Regeneration and Insilico Medicine, demonstrated the close resemblance of iPSCs with ESCs at the pathway level, and provided examples of how pathway activity analysis can be applied to identify iPSC line abnormalities or to predict in vitro differentiation potential. The results indicate that pathway activation profiling is a promising strategy for evaluating the safety and potency of iPSC lines in translational medicine applications, allowing scientists to test differentiation abilities of many iPSC lines in silico while saving valuable time for patients waiting for treatment. The original paper, “Quantifying signaling pathway activation to monitor the quality of induced pluripotent stem cells,” was published in the last Oncotarget journal issue:

Evgeny Makarev, Ph.D, COO of Atlas Regeneration, Inc., the leader of the study, said, "Regeneration Intelligence is unique among pathway analysis platforms. Using our algorithm along with a proprietary pathway database, we established for the first time pathway activation profiles of iPS. We reused data from publicly available gene expression data sets and evaluated signaling and metabolic pathway activation profiles for 20 human embryonic stem cell (ESC) lines, 12 human iPSC lines. Consequently, we identified PAS quality score lines as a novel prognostic biomarker that can identify impaired iPSC lines."

Anthony Atala, MD, Director of Atlas Regeneration, said, "Our Regeneration Intelligence platform has been used in many iPSC lines and is helping stem cells biologists to improve and speed up decision-making. Unfortunately, the entire process of verification and validation of differentiation abilities using in vitro differentiation assays typically takes 12 weeks and time is critical for definitive treatment, especially in urgent cases. With the help of Regeneration Intelligence, we may be able to significantly reduce the time and cost of the process."

About Atlas Regeneration, Inc.
Atlas Regeneration is a Winston Salem, N.C.-based company utilizing advances in multiomics and big data analysis for drug discovery and regeneration targeting aging and age-related diseases. The company utilizes the Regeneration Intelligence™ and PharmAtlas™ packages for pathway analysis in aging and stem cells research, pursues internal drug discovery programs, and provides services to pharmaceutical companies. For more info, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Eugene Makarev
Atlas Regeneration
+1 3015257263
Email >
Visit website